Unable to Reach Licensing Deal, Rosetta Genomics Will Not Receive $1.25M Payment | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Unable to reach a licensing deal with a lender, Rosetta Genomics will not receive a $1.25 million payment, the company disclosed in a document filed with the US Securities and Exchange Commission today.

Rosetta and the unnamed lender had agreed to negotiate for the licensing deal as part of a $1.75 million private placement raise that Rosetta announced in late January.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.